Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury

Inclusion Criteria: 1. The patient is completely voluntary and has the ability to sign the research informed consent form within 30 days before enrollment; 2. Age ≥18 years old and ≤65 years old; 3. Pathologically confirmed cervical cancer; 4. Those with IB3, IIA2, IIB, IIIA, IIIB, and those with cervical tumor ≥ 4cm or involved parametrial in IIIC1 and IIIC2 (FIGO 2018 staging); 5. ECOG score 0-2 points; 6. The complete blood count and basal metabolic indexes in the 14 days before enrollment must meet the following requirements: NEUT≥1.5\*10\^9/L, HGB≥80g/L, PLT≥100\*10\^9/L, blood creatinine \< 1.5mg/dl (133umol/L), AST and ALT are within 2 times of the upper limit of normal; 7. Those who have had regular bowel movements and had a negative stool routine test + occult blood before enrollment. Exclusion Criteria: 1. Those who have a history of allergy to superoxide dismutase use; 2. Patients with skin and mucous membrane infections, patients with obvious empyema or pelvic inflammatory disease; 3. Those who have had chronic colitis, ulcerative colitis, and non-specific proctitis in the past; 4. Those who have received cervical cancer surgery (including pelvic or retroperitoneal lymphadenectomy, excluding tumor biopsy), radiotherapy or chemotherapy; 5. Those who are expected to be unable to receive brachytherapy, or brachytherapy needs to use tumor elimination, uterine tube inserted alone in one fraction, or template plan; 6. Those who need to use fluorouracil or capecitabine or tigio in the concurrent chemotherapy regimen; 7. History of other malignant tumors; 8. Pregnant or lactating women; 9. Accompanied by active infection and fever; 10. Other serious diseases that may significantly affect the compliance of clinical trials, such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, and mental illness that require treatment.